[1] Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer[J]. J Urol, 1999, 161(2):388-94. [2] Pode D,Shápiro A, Wald M, et al. Noninvasive detection of bladder cancer with the BTA stat test[J]. J Urol, 1999, 161(2): 443-6. [3] Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive cost effective test in patients at risk for bladder cancer[J]. J Urol, 1999, 161 (1): 62-5. [4] Schmetter BS, Habicht KK, Lamm DL, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer[J]. J Urol, 1997, 158(3Pt 1): 801-5. [5] Kavaler E, Landman J, Chang Y, et al. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity[J]. Cancer, 1998, 82(4): 709-14. [6] Brown FM. Urine cytology: it is still the gold standard for screening[J] ? Urol Clin North Am, 2000, 27(1)i 25-37. [7] Hanski C, Hofmeier M, Schmitt-GraffA, et al. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast and ovary[J]. J Pathol,1997, 182(4): 385-91. [8] Hilkins J, Ligtenberg MJ, Vos HL, et al. Cell membrane-associated mucins and their adhesion-modulating property[J]. TIBS, 1992, 17(9): 259-363. [9] Wesseling J, Vandervalk SW, Vos HL, et al. Epithialin (MUC1)overexpressoin inhibits integrin-mediated adhesion to extracellular matrix components[J]. Cell Biol, 1995, 129(1): 255-65. [10] Hanski C, Drechsler K, Hanisch FG, et al. Altered glycosylation of the MUC 1 protein core contributes to colon carcinoma-associated increase of mucin bound sialyl-Lewis (x) expression[J]. Cancer Res, 1993, 53(17): 4082-8. [11] Simms MS, Hughes OD, Limb M, et al. MUC1 mucin as a tumor marker in bladder cancer[J]. BJU Int, 1999, 84(3): 350-2. [12] Lwase H, Kobayash S, Itoh Y, et al. Evaluation of serum tumor markers in patients with advance or recurrent breast cancer[J].Breast Cancer Res Treat, 1994, 33(3): 83-8. |